Diagnostics Startups funded by Y Combinator (YC) in the San Francisco Bay Area 2026

We know how to improve cancer outcomes by 8x-10x: you catch it early. MRI is the most robust and powerful cancer-detection tool in the world, yet systems cost millions to purchase, take months to install, and require high levels of technical skill to operate. We've redesigned MRI from the ground up with new physics, algorithms, and hardware, all to bring cancer screening to the entire world. Our mobile MRI is an imaging clinic on wheels. No equipment to buy, no infrastructure needed. For a flat per-scan fee, any medical site can offer MRI cancer screening. Starting with prostate cancer. Then everything else.

We're building the HaploHub: a SaaS platform for genetic testing labs, concierge medical practices, and payer/providers to: * predict disease risk for their patients based on proprietary or publicly available genetic models * securely host, manage, and interrogate the genetic data of their population * generate reports and run the most common inference algorithms (phasing, imputation, ibd, etc.) without writing code

Digital health holds a lot of potential but is ignoring a growing problem: diagnostic testing. Without this data, providers and organizations will be limited in the services they can provide patients at home. Scout has developed a platform - Hub, test kits, and app - that delivers health testing at home with 10x lower development cost and 3x lower per-test price. Our patented tech also meets performance requirements for medical diagnoses and integrates with the current healthcare tech stack. Scout’s technology is poised to disrupt the outdated $33Bn diagnostic market by democratizing testing while dramatically improving the patient experience. Scout has received $16M in non-dilutive funding from the NIH and other organizations to fully de-risk our platform, and our pipeline includes a diverse test menu for primary care (e.g. respiratory and sexual health), wellness (e.g. gut health), and chronic conditions (e.g. certain cancers). We have already received FDA authorization for our platform in clinical settings and are planning to launch our flagship Scout Hub in 2024.

We turn advances in AI and protein design into experimentally validated molecular tools, partnering with research teams and diagnostic developers to deliver high-performance affinity reagents in weeks, not months.

Leveraging AI to provide veterinarians with more accurate and affordable diagnostics.

Segmed provides at-scale access to novel clinical data globally, offering millions of diagnostic-grade medical images to accelerate innovation and mature the evidence needs of life sciences and technology industry. ‍ Our solutions allow you to access a Real World Data (RWD) network to facilitate rapid discovery and investigational capability of imaging data, development of early disease detection & prediction models, improved patient recruitment and reduced operating burden to access therapeutic data ecosystem.

Probably Genetic is changing the lives of patients living with severe, complex diseases. Our data platform is used by drug developers and patient advocacy groups to develop and launch treatments for these patients. Our technology discovers undiagnosed patients online, analyzes their disease state using machine learning and at-home testing, and enables compliant communication with patients. In doing so, we help patients access diagnoses, clinical trials, and treatments as early as possible.

BrainKey is an AI-driven digital healthcare company with a mission to create a world free from dementia.

Rev Genomics is a plant biotechnology company that provides breeders, growers, and retailers with novel cultivars to differentiate themselves in high value markets.

Novel quantitative virtual microscopy for early detection of Alzheimer's disease from non-invasive MRI.

BillionToOne has developed a DNA molecular counter that increases the cell-free DNA diagnostics resolution by over 1,000 fold, which unlocks transformative improvements in prenatal screening and liquid biopsy for cancers. Unity Screen, BillionToOne's commercially available non-invasive prenatal test (NIPT), is the only NIPT that can assess fetal risk for both recessive conditions and aneuploidies from maternal blood. UNITY Screen continues to grow exponentially and is on its path to becoming the next standard-of-care, with an increasing number of publications showing its accuracy and advantages over other screening methods. We have also recently used our molecular counting technology to develop liquid biopsy tests, which have the potential to completely transform oncology care.

Diassess Inc. is revolutionizing the way infectious diseases are prevented, diagnosed, and monitored by developing the tools necessary to empower people to become knowledgeable about their health. We produce inexpensive, disposable health diagnostic hardware that transforms any smartphone into a portable, real-time health-monitoring device for rapid, accessible, multiplexed analysis of bodily fluids anywhere in the world.

Notable Labs is building a personalized drug discovery platform to identify treatment options for relapsed and refractory cancer patients — starting with blood cancer — to address the long tail of cancer treatment. We look at a person’s actual cancer cells, test combinations of FDA approved drugs, and see which combinations kill the cancer cells and leave the healthy cells alive. We focus on combinations because cancer is often difficult to target with just one drug and starting with a single drug can lead to resistant clones or relapse. We're building a highly automated lab in Foster City running on our custom software and are currently testing relapsed/refractory cancer patients as well as samples from a variety of pharma/biotech partnerships. https://www.notablelabs.com/careers

Luminist developed a non-invasive diagnostic test for the early detection and staging of liver fibrosis and non-alcoholic steatohepatitis (NASH). Luminist was acquired in 2020 by DiscernDx.

Loop Genomics provides long-read sequencing solutions across a diverse set of research and clinical applications. Our platform for long-read DNA sequencing transforms short-read DNA sequencers into long-read sequencing machines.